Investments
29Portfolio Exits
7Funds
1About City Hill Ventures
City Hill Ventures is a health care-focused venture capital firm based in San Diego, California. City Hill Ventures makes primarily seed and early-stage investments in private companies in life sciences (therapeutics, diagnostics, medical devices) and health care technology (information technology, wireless), with target aggregate investment in a given company ranging from approximately $200,000 to $2 million.
Want to inform investors similar to City Hill Ventures about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Expert Collections containing City Hill Ventures
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find City Hill Ventures in 1 Expert Collection, including Vitamin & Supplement Startups.
Vitamin & Supplement Startups
237 items
Latest City Hill Ventures News
May 17, 2023
May 17, 2023 Boundless Bio , a San Diego, CA-based clinical stage precision oncology company, raised $100M in Series C funding. The round was co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and RA Capital Management, with participation from Sectoral Asset Management, Piper Heartland Healthcare Capital and existing investors Fidelity Management & Research Company LLC, ARCH Venture Partners, Nextech Invest, Wellington Management, Vertex Ventures HC, Redmile Group, Surveyor Capital (a Citadel company), GT Healthcare Capital Partners, Alexandria Venture Investments, PFM Health Sciences, Logos Capital, and City Hill Ventures. In conjunction with the financing, Fabio Pucci, Ph.D., Senior Director of Venture Investments Health at Leaps by Bayer, will join the Boundless Bio Board of Directors. Led by CEO and President Zachary Hornby, Boundless Bio is a clinical stage, precision oncology company dedicated to the discovery and development of new drugs targeting a novel area of cancer biology, ecDNA, to deliver transformative therapies intended to improve and extend the lives of patients with oncogene amplified cancers. The company intends to use the funds to advance BBI-355, an ecDNA-directed therapy (ecDTx), through meaningful clinical readouts from its ongoing Phase 1/2 clinical trial in patients with oncogene-amplified cancers, and a preclinical pipeline of differentiated ecDTx candidates and its proprietary ecDNA diagnostic clinical trial assay, ECHO (ecDNA Harboring Oncogenes), which is being developed in partnership with SOPHiA GENETICS.
City Hill Ventures Investments
29 Investments
City Hill Ventures has made 29 investments. Their latest investment was in Boundless Bio as part of their Series C on May 5, 2023.
City Hill Ventures Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
5/16/2023 | Series C | Boundless Bio | $100M | No | Alexandria Venture Investments, ARCH Venture Partners, City Hill Ventures, Fidelity Investments, GT Healthcare Capital Partners, Leaps by Bayer, Logos Capital, Nextech Invest, PFM Health Sciences, Piper Heartland Healthcare Capital, RA Capital Management, Redmile Group, Sectoral Asset Management, Surveyor Capital, Vertex Ventures HC, and Wellington Management | 8 |
1/10/2022 | Series C | Maze Therapeutics | $190M | No | 8 | |
12/8/2021 | Series B | OncoMyx Therapeutics | $50M | No | 17 | |
4/28/2021 | Series B | |||||
4/27/2020 | Series B |
Date | 5/16/2023 | 1/10/2022 | 12/8/2021 | 4/28/2021 | 4/27/2020 |
|---|---|---|---|---|---|
Round | Series C | Series C | Series B | Series B | Series B |
Company | Boundless Bio | Maze Therapeutics | OncoMyx Therapeutics | ||
Amount | $100M | $190M | $50M | ||
New? | No | No | No | ||
Co-Investors | Alexandria Venture Investments, ARCH Venture Partners, City Hill Ventures, Fidelity Investments, GT Healthcare Capital Partners, Leaps by Bayer, Logos Capital, Nextech Invest, PFM Health Sciences, Piper Heartland Healthcare Capital, RA Capital Management, Redmile Group, Sectoral Asset Management, Surveyor Capital, Vertex Ventures HC, and Wellington Management | ||||
Sources | 8 | 8 | 17 |
City Hill Ventures Portfolio Exits
7 Portfolio Exits
City Hill Ventures has 7 portfolio exits. Their latest portfolio exit was Erasca on July 16, 2021.
City Hill Ventures Fund History
1 Fund History
City Hill Ventures has 1 fund, including City Hill Venture Partners I LLC.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
City Hill Venture Partners I LLC | Early-Stage Venture Capital | Open | 1 |
Closing Date | |
|---|---|
Fund | City Hill Venture Partners I LLC |
Fund Type | Early-Stage Venture Capital |
Status | Open |
Amount | |
Sources | 1 |
City Hill Ventures Team
1 Team Member
City Hill Ventures has 1 team member, including current Controller, Karen Gilmore.
Name | Work History | Title | Status |
|---|---|---|---|
Karen Gilmore | Controller | Current |
Name | Karen Gilmore |
|---|---|
Work History | |
Title | Controller |
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
